Document Detail

Randomized Phase II trial of thalidomide alone versus thalidomide plus interferon alpha in patients with refractory multiple myeloma.
MedLine Citation:
PMID:  17530483     Owner:  NLM     Status:  MEDLINE    
The potential synergistic anti-myeloma effect for thalidomide combining with interferon alpha was not yet clear clinically. From March 2001 to January 2004, a total of 28 heavily pretreated multiple myleoma (MM) patients were enrolled in this open-labeled, randomized Phase II study. Patients with refractory MM were randomized to receive either thalidomide alone (200 mg/day up to the maximum dose 800 mg/day, arm B) or the combination of thalidomide and interferon alpha (3 MIU/m(2) subcutaneous injection 3 times weekly, arm A). The objective of this study was to compare the safety and efficacy of thalidomide alone to combined regimen. The patients' characteristics were similar between the 2 arms. However, the average treatment duration was significantly longer in the arm B than the arm A (236 days versus 101 days, p = 0.029). Serum levels of paraprotein decline >/= 25 percent were obtained in 6 of 12 patients (50.0 percent) treated with arm B and 3 of the 16 patients (18.8 percent) treated with arm A. The estimated time to event was 7.9 months (95 percent confidence interval [95%CI], 0.5-15.4) for arm B and 1.5 months (95%CI, 0.0-3.4) for arm A (log-rank test, p = 0.0193). The major adverse events in both arms consisted of neutropenia, anemia, thrombocytopenia, constipation, somnolence, and skin rash. Our study showed that thalidomide alone was effective and tolerated in patients with relapsed or refractory MM. The thalidomide combined with interferon alpha resulted in a lower frequency of paraprotein response, shorter treatment-duration and 25 percent of patients' refusing rate. It may be concluded that the combined regimen is not well tolerated in our patients and needed to be further evaluated in the future.
Tzeon-Jye Chiou; Teng-Hsu Wang; Tsu-Yi Chao; Sheng-Fung Lin; Jih-Luh Tang; Tsai-Yun Chen; Ming-Chih Chang; Erh-Jung Hsueh; Po-Min Chen
Related Documents :
1752373 - Efficacy of long term recombinant interferon-alfa in patients with chronic hepatitis c....
12820143 - Long-term outcomes of thymosin-alpha 1 and interferon alpha-2b combination therapy in p...
18043103 - Open right colectomy is still effective compared to laparoscopy: results of a randomize...
Publication Detail:
Type:  Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Cancer investigation     Volume:  25     ISSN:  0735-7907     ISO Abbreviation:  Cancer Invest.     Publication Date:    2007 Apr-May
Date Detail:
Created Date:  2007-05-28     Completed Date:  2007-07-03     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8307154     Medline TA:  Cancer Invest     Country:  United States    
Other Details:
Languages:  eng     Pagination:  140-7     Citation Subset:  IM    
Section of Medical Oncology, Department of Medicine, Taipei Veterans General Hospital and National Yang-Ming University School of Medicine, Taipei, Taiwan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Combined Chemotherapy Protocols / adverse effects,  therapeutic use*
Drug Administration Schedule
Injections, Subcutaneous
Interferon Alfa-2b / administration & dosage
Kaplan-Meiers Estimate
Middle Aged
Multiple Myeloma / blood,  drug therapy*,  mortality
Myeloma Proteins / metabolism
Paraproteins / metabolism
Taiwan / epidemiology
Thalidomide / administration & dosage
Time Factors
Treatment Failure
Treatment Outcome
Treatment Refusal
Reg. No./Substance:
0/Myeloma Proteins; 0/Paraproteins; 50-35-1/Thalidomide; 99210-65-8/Interferon Alfa-2b

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Tropisetron, ondansetron, and granisetron for control of chemotherapy-induced emesis in Turkish canc...
Next Document:  A Phase I dose-finding study using an innovative sequential biweekly schedule of irinotecan followed...